Lazard Capital Analysts Begin Coverage on MedAssets (MDAS)

By admin | 6 years ago

Research analysts at Lazard Capital began coverage on shares of MedAssets (NASDAQ: MDAS) in a report released on Wednesday. The firm set a “buy” rating on the stock.

Shares of MedAssets traded down 1.30% during mid-day trading on Wednesday, hitting $11.42. MedAssets has a 52 week low of $8.52 and a 52 week high of $16.28. The company has a market cap of $666.0 million and a P/E ratio of 1928.33.

MedAssets last announced its earnings results on Wednesday, May 2nd. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.06. The company’s quarterly revenue was up 14.9% on a year-over-year basis. On average, analysts predict that MedAssets will post $0.26 earnings per share next quarter.

A number of other analysts have also recently weighed in on MDAS. Analysts at Auriga reiterated a “buy” rating on shares of MedAssets in a research note to investors on Thursday, May 3rd. Finally, analysts at Caris & Co. downgraded shares of MedAssets from an “above average” rating to an “average” rating in a research note to investors on Monday, February 27th.

MedAssets, Inc. provides technology-enabled products and services. These solutions are designed to improve operating margin and cash flow for hospitals and health systems.

About the author